Vanila-E 200 Tablet 15 pcs
৳ 57
Order By Call:
+88 01540 384 786 (Mobile)
+88 01819 479 004 (WhatsApp)
Vanila-E is a medicine used in the treatment of conditions caused due to low levels of vitamin B3 in the body. It helps in maintenance of normal cholesterol level. It also helps in the treatment of symptoms like loss of appetite, weakness, diarrhea, skin inflammation, and mental changes. Vanila-E can be taken with or without food. It should be taken regularly and at the same time each day to get the most benefit from it. This medicine may be only part of a complete program of treatment that also includes making changes to your diet and taking calcium and vitamin supplements. Learn about the foods you should eat to make sure you get enough vitamins in your diet. This medicine may cause few side effects such as itching, flushing (sense of warmth in the face, ears, neck and trunk), redness of skin, and tingling in some patients. If any of these side effects bothers you, consult with your doctor. Before taking this medicine, tell your doctor if you have any heart, kidney, or liver disease. Some other medicines can decrease the absorption of vitamins, so let your doctor know all other medicines you are taking to make sure you are safe. It is important to ask the advice of you doctor before taking any other vitamin supplements.
Payment Methods
About the Product
Full Description
Indication
Hyperlipidaemias, Nicotinic acid deficiency, Ischaemic events
Administration
Should be taken with food. Take at bedtime after a low-fat snack.
Adult Dose
Oral Treatment and prophylaxis of nicotinic acid deficiency Adult: For treatment of pellagra: 300-500 mg daily in divided doses. For management of Hartnup disease: 50-200 mg daily. Hyperlipidaemias Adult: Initially, 250 mg once daily in the evening. Increase dose every 4-7 days until desired LDL cholesterol and/or triglyceride level is achieved or dose of 1.5-2 g/day is reached. If hyperlipidaemia is not adequately controlled after 2 mth w/ this dose, it can be increased at 2- to 4-wk intervals to 1 g tid. Max: 6 g daily. As extended-release tab: Initially, 500 mg/day PO at bedtime initially; dose adjusted every 4 weeks on basis of effect and tolerance to therapeutic dose of 1-2 g once daily; not to exceed 1-2 g/day Vasodilation Adult: 100-150 mg 3-5 times daily. As extended-release tab: 300-400 mg 12 hrly.
Child Dose
Oral Treatment and prophylaxis of nicotinic acid deficiency Child: For treatment of pellagra: 100-300 mg daily in divided doses.
Contraindication
Niacin is contraindicated in patients with a known hypersensitivity to Niacin or any component of this medication, significant or unexplained hepatic dysfunction, active peptic ulcer disease or arterial bleeding.
Mode of Action
Nicotinic acid is a derivative of vitamin B3 and is incorporated into coenzymes nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), which are involved in multiple cellular metabolic pathways. Nicotinic acid also reduces total serum cholesterol, LDL, VLDL, and triglycerides, and increases HDL cholesterol. It appears to decrease hepatic synthesis of VLDL, however, the exact mechanisms of nicotinic acid's antilipemic effects are unknown and are unrelated to its role as a vitamin.
Precaution
Patient w/ unstable angina, acute MI, CHD, DM, gout, history of peptic ulceration. Patient who consume large amount of alcohol. Patient undergoing surgery. Renal or hepatic impairment. Pregnancy and lactation. Monitoring Parameters Monitor LFTs and blood glucose frequently.
Side Effect
Flushing, sensation of heat, faintness, pounding in the head, tingling, itching, headache, dizziness, tachycardia, palpitations, dyspnoea, sweating, chills, oedema; dryness of skin, pruritus, hyperpigmentation, rash, cramps, cough, diarrhoea, nausea and vomiting, anorexia, activation of peptic ulcer, eye disorders including cystoid macular oedema and toxic amblyopia; decreased glucose tolerance, hyperglycaemia, hyperuricaemia; abnormal LFTs, jaundice; hypophosphataemia, reduced platelet counts, prolonged prothrombin time, arrhythmias, hypersensitivity reactions including angioedema; insomnia, myalgia and hypotension.
Interaction
Increased risk of myopathy and rhabdomyolysis w/ concomitant HMG-CoA reductase inhibitors. Reduced bioavailability w/ colestyramine or colestipol. Decreased metabolic clearance w/ aspirin. May potentiate effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension.
